J Biol Chem, Vol. 275, Issue 13, 9193-9200, March 31, 2000
Gonadotropin-releasing Hormone Receptor Initiates Multiple
Signaling Pathways by Exclusively Coupling to Gq/11
Proteins*
Robert
Grosse,
Andrea
Schmid,
Torsten
Schöneberg,
Andreas
Herrlich,
Peter
Muhn
,
Günter
Schultz, and
Thomas
Gudermann§
From the Institut für Pharmakologie, Freie Universität
Berlin, Thielallee 69-73, D-14195 Berlin, Germany and the
Forschungslaboratorien der Schering AG, 13342 Berlin,
Germany
 |
ABSTRACT |
The agonist-bound gonadotropin-releasing hormone
(GnRH) receptor engages several distinct signaling cascades, and it has
recently been proposed that coupling of a single type of receptor to
multiple G proteins (Gq, Gs, and
Gi) is responsible for this behavior. GnRH-dependent signaling was studied in gonadotropic
T3-1 cells endogenously expressing the murine receptor and in
CHO-K1 (CHO#3) and COS-7 cells transfected with the human GnRH receptor
cDNA. In all cell systems studied, GnRH-induced phospholipase C
activation and Ca2+ mobilization was pertussis
toxin-insensitive, as was GnRH-mediated extracellular signal-regulated
kinase activation. Whereas the Gi-coupled m2 muscarinic
receptor interacted with a chimeric Gs protein
(Gsi5) containing the C-terminal five amino acids of
G
i2, the human GnRH receptor was unable to activate the
G protein chimera. GnRH challenge of
T3-1, CHO#3 and of GnRH
receptor-expressing COS-7 cells did not result in
agonist-dependent cAMP formation. GnRH challenge of CHO#3
cells expressing a cAMP-responsive element-driven firefly luciferase
did not result in increased reporter gene expression. However,
coexpression of the human GnRH receptor and adenylyl cyclase I in COS-7
cells led to clearly discernible GnRH-dependent cAMP
formation subsequent to GnRH-elicited rises in
[Ca2+]i. In
T3-1 and CHO#3 cell membranes,
addition of [
-32P]GTP azidoanilide resulted in GnRH
receptor-dependent labeling of G
q/11 but not
of G
i, G
s or G
12/13
proteins. Thus, the murine and human GnRH receptors exclusively couple
to G proteins of the Gq/11 family. Multiple
GnRH-dependent signaling pathways are therefore initiated
downstream of the receptor/G protein interface and are not indicative
of a multiple G protein coupling potential of the GnRH receptor.
 |
INTRODUCTION |
The decapeptide GnRH1
plays a central role in the neuroendocrine control of reproduction.
GnRH is synthesized in the hypothalamus and released into the
hypophyseal portal circulation in a pulsatile fashion to interact with
a membranous receptor on gonadotropes in the anterior pituitary gland
(1). In these cells, the synthesis and the secretion of gonadotropins
is subject to differential regulation by GnRH (2), and the neuropeptide
is additionally involved in the long term maintenance of the
gonadotrope phenotype (3). Cloning of cDNAs coding for GnRH
receptors of various species demonstrated that GnRH interacts with a
membrane receptor belonging to the large superfamily of heptahelical G
protein-coupled receptors (2, 4).
Apart from the effects of GnRH on the hypothalamic-pituitary-gonadal
axis, extrapituitary actions in the central and peripheral nervous
system, as well as in several extraneural and also in neoplastic
tissues have been described (5). Current evidence is consistent with
the notion of an autocrine/paracrine regulatory GnRH system exerting a
growth regulatory effect on various cell types (6). In a number of
human malignancies, such as breast, ovary, endometrium, and prostate
cancers, the expression of GnRH and its receptor, as well as a direct
antiproliferative effect of GnRH analogues, could be demonstrated
(7-9). Most notably, the nucleotide sequence of the GnRH receptor in
breast, ovarian, and prostate cancer cells is identical to that
expressed in the pituitary gland (10). In vivo studies with
nude mice strongly suggest that the antitumor activity of a GnRH
receptor antagonist is not only exerted through suppression of the
pituitary-gonadal axis but also through a direct effect of the GnRH
analogue on tumor cells (11).
Considering the plethora of cellular effects elicited by GnRH, one may
ask where whithin the neuropeptide-induced signal transduction cascade
divergent pathways are engaged. One potential answer would be to
postulate an inherent ability of the GnRH receptor to couple to
multiple G proteins, which would then enable the receptor to activate
multiple signal transduction pathways (2, 12). This view, however, is
not uncontested, and despite the deluge of circumstantial evidence,
direct proof of the activation of multiple G proteins by the
agonist-bound GnRH receptor is still missing.
To better understand the cellular actions of GnRH and its analogues, we
set out to study the G protein coupling profile of the murine GnRH
receptor, endogenously expressed in
T3-1 cells, and of the human
receptor expressed in CHO and COS-7 cells. We provide direct evidence
that the GnRH receptor in its native environment exclusively couples to
Gq/11 proteins. Therefore, divergent GnRH-induced signal
transduction is determined downstream of the receptor/G protein interface.
 |
EXPERIMENTAL PROCEDURES |
Materials
All chemicals were obtained from Sigma with the following
exceptions: buserelin was purchased from Welding, and the ECL system and myo-[3H]inositol (18.6 Ci/mmol) were from
Amersham Pharmacia Biotech. Pertussis toxin (PTX) and cholera toxin
(CTX) were from List Biological Laboratories, and human chorionic
gonadotropin was from Calbiochem. LipofectAMINE was obtained from Life
Technologies, fura-2/AM was from Molecular Probes, Dowex 1-X8 100 mesh
resin was from Bio-Rad, and rabbit polyclonal anti-ERK2 antibody was
from Santa Cruz Biotechnology. Cetrorelix was a gift from Schering AG.
The adenylyl cyclase type I (AC-I) cDNA was a gift from Dr. A. G. Gilman. Human V2 vasopressin receptor, m2 muscarinic receptor, and
Gsi5 cDNAs were provided by Dr. J. Wess, and the
plasmid pADneo2-C6-BGL was provided by Dr. A. F. Czernilofsky
(13). Cell culture medium and supplies were from Life Technologies, Inc.
Methods
Cell Culture and Transfection--
COS-7 and
T3-1 cells were
cultured in DMEM containing 10% heat-inactivated fetal calf serum,
penicillin (50 units/ml), and streptomycin (50 µg/ml) under 7%
CO2 at 37 C°. For transfections, 1 × 106 cells were seeded into 60-mm dishes. Twenty-four hours
later, cells were transfected with various cDNA constructs (3 µg
of plasmid DNA per dish) by lipofection. Cells permanently expressing
the human GnRH receptor (CHO#3) and the human V2 vasopressin receptor (CHO V2-R) were generated as described before by double selection cotransfecting the puromycin and hygromycin resistance plasmids pBSpac
p and pSK/HMR272, respectively (14, 15). Single cell clones
were obtained following a limited dilution procedure. CHO#3 and CHO
V2-R cells were cultured in Ham's F-12 medium as described above.
Radioactive Labeling of Buserelin--
Buserelin was labeled
with 125I by the chloramine T method at the Department of
Isotope Chemistry of Schering AG. The tracer was purified by
reverse-phase high pressure liquid chromatography on a Spherisorb ODS
II column by eluting with 50% acetonitrile, 0.15% trifluoroacetic
acid at a flow rate of 0.5 ml/min. The retention time of
mono-125I-buserelin was approximately 23 min. The specific
activity of the tracer was 2000 Ci/mmol.
Membrane Preparation--
Plasma membranes were prepared from
cells grown to confluence. Cells were harvested; pelleted (1000 × g for 10 min); resuspended in a buffer consisting of 0.25 M sucrose, 0.01 M triethanolamine, pH 7.4; and
subsequently disrupted by nitrogen cavitation. Nuclei were pelleted at
750 × g for 5 min, and the supernatant was centrifuged at 30,000 × g for 30 min at 4 °C. Membrane pellets
were homogenized in a glass-Teflon homogenizer in assay buffer (0.25 M sucrose, 0.01 M triethanolamine, pH 7.4, ovalbumin 1 mg/ml) and stored as 200-µl aliquots at
70 °C. The
protein content of samples was determined by the method of Bradford
(16).
Radioligand Binding Assays--
Saturation binding studies were
performed with 10 µg of membrane protein for
T3-1 and 40 µg for
CHO#3 cells, 1500-200,000 cpm 125I-buserelin, and assay
buffer in an incubation volume of 100 µl per sample. Incubations were
carried out for 90 min at room temperature. Nonspecific binding was
determined in the presence of excess unlabeled buserelin
(10
6 M). Bound and free ligand were separated
by filtration on Whatman GF/C filters using an Amicon 10-fold sampling
device. Filters were presoaked with 0.3% polyethyleneimine for 30 min
in order to reduce nonspecific binding. The filters were washed twice
with 5 ml 0.02 M Tris/HCl, pH 7.4. Bound radioactivity was
determined with a
-counter. Binding data were analyzed with the help
of the computer program LIGAND (17).
Measurement of Intracellular Inositol Phosphate and cAMP
Accumulation--
For cAMP and inositol phosphate (IP) measurements,
cells were seeded into 12-well plates (3 × 105
cells/well for
T3-1 and CHO#3 cells; 2 × 105
cells/well for COS-7 cells) 3 days prior to functional assays. For cAMP
determinations, cells were washed once in serum-free DMEM, followed by
a 20-min preincubation with the same medium containing 1 mM
3-isobutyl-1-methylxanthine (Sigma) for 20 min at 37 °C in a
humidified 7% CO2 incubator. Subsequently, cells were
stimulated with appropriate concentrations of agonist or antagonist for
1 h. Reactions were terminated by aspiration of the medium and
addition of 1 ml 5% trichloroacetic acid. The cAMP content of the cell
extracts was determined as described previously (15). For IP
determinations, cells were incubated with 2 µCi/ml of
myo-[3H]inositol for 18 h. Thereafter,
cells were washed once with serum-free DMEM containing 10 mM LiCl. Agonist-induced increases in intracellular IP
levels were determined by anion exchange chromatography.
Measurement of Intracellular Ca2+
Mobilization--
Determination of [Ca2+]i was
performed after loading of cells with 5 µM fura-2/AM as
described previously (18). Briefly, semiconfluent grown cells were
detached and incubated (2 × 107 cells/ml) in
incubation buffer (138 mM NaCl, 6 mM KCl, 1 mM MgSO4, 1 mM CaCl2, 1 mM Na2HPO4, 5 mM
NaHCO3, 5, 5 mM glucose, 10 mM HEPES, 0.1% bovine serum albumin, pH 7.4) containing 5 µM fura-2/AM for 30 min at 37 °C. The cells were then
pelleted and resuspended at a density of 1 × 106
cells/ml in incubation buffer in 2-ml aliquots at room temperature in
the dark until used. To obtain Rmax and
Rmin, Triton X-100 (reduced form, Sigma; final
concentration, 0.1%) and EGTA (pH 8.5; final concentration, 20 mM) were added sequentially to the cell suspensions.
Autofluorescence was recorded in the presence of 20 mM
MnCl2. Concentration of cytosolic Ca2+ was
calculated according to Grynkiewicz et al. (19).
cAMP Response Element-dependent Luciferase
Assays--
For luciferase assays CHO cells permanently expressing the
human GnRH receptor (CHO#3) or the human V2 receptor (CHO-V2-R) were
transiently transfected with the plasmid pADneo2-C6-BGL containing six
heterologous cAMP-responsive element sequences. Two days later, cells
were stimulated for 5 h with 20 µM forskolin, 1 µM GnRH, or 100 nM arginine-vasopressin
(AVP). After removal of the incubation medium, cells were washed with
phosphate-buffered saline and subsequently lysed in assay buffer
containing ATP and 1% Triton X-100. After luciferin addition the
luciferase activity was measured in a Lumat LB9501 luminometer (Berthold).
ERK Activity Assays--
For ERK mobility shift assays,
T3-1
cells (5 × 105 cells/well) were grown to confluence
in six-well dishes, washed once with phosphate-buffered saline, and
incubated in serum-free DMEM for 16 h in the absence or presence
of PTX (0.1 µg/ml). Thereafter, cells were washed with
phosphate-buffered saline again and treated for 10 min with various
compounds (see figure legend) dissolved in DMEM. After an additional
washing step with ice-cold phosphate-buffered saline, the cells were
lysed on ice in SDS sample buffer (pH 6.8). Lysates were sonicated and
boiled for 3 min. Forty µl of these lysates were used for
SDS-polyacrylamide gel electrophoresis on 10% polyacrylamid gels run
at 10 mA overnight. ERK2 was detected with anti-ERK2 antibodies by immunoblotting.
For immune complex kinase assays, endogenously expressed ERK was
immunoprecipitated with ERK2 antibodies and protein A-Sepharose from
T3-1 cells grown to semiconfluence in 100-mm dishes. Immune complexes were washed three times with kinase buffer (40 mM
HEPES, pH 7.5, 5 mM magnesium acetate, 2 mM
dithiothreitol, 1 mM EGTA and 200 µM
Na3VO4), and reactions were performed with 250 µg/ml myelin basic protein (Sigma). The kinase assay was started in the presence of 50 µM ATP solution containing 2 µCi of
[
-32P]ATP (NEN Life Science Products). Incubations
were carried out at room temperature for 20 min and were terminated by
the addition of 88% formic acid. Reaction mixtures were then spotted
onto Whatman p81 chromatography paper and washed four times in 150 mM phosphoric acid. Incorporated radioactivity was
determined by liquid scintillation spectrometry. All assays were
performed in duplicate. Basal cpm values in independent experiments
ranged between 1500 and 7000 cpm, whereas probes without ERK2 antibody
were below 150 cpm.
Photolabeling of Receptor-activated G
Proteins--
Photolabeling of membrane G proteins and
immunoprecipitation were performed as described previously (20). The
following antisera were used: AS 348 (
s), AS 370 (
q/11), AS 233 (
12), AS 343 (
13), AS 266 (
i common), and AS 6 (
o common). Antisera were raised against peptides
corresponding to specific regions of G protein
subunits and have
been described before (20, 21). Immunoprecipitated G protein
subunits were separated on 13% polyacrylamide gels and visualized by
autoradiography of dried gels with Kodak X-Omat AR-5 films (Eastman
Kodak Co.) or with a phosphoimaging screen.
 |
RESULTS |
Membrane Expression of the Mouse and Human GnRH Receptor in
T3-1 and CHO#3 Cells--
To functionally characterize the human
GnRH receptor (22), CHO-K1 cells were generated that permanently
express the human receptor. The CHO#3 cells used throughout this study
represent one clonal cell line isolated by limiting dilution. To
compare ligand binding properties of the mouse and human GnRH
receptors, membranes prepared from
T3-1 and CHO#3 cells were
incubated with the agonist 125I-buserelin. The radioligand
bound to both membrane preparations in a saturable and specific manner.
Scatchard transformation of the binding data (Fig.
1) revealed a single high affinity
binding site for mouse and human GnRH receptors, with
Kd values of 0.29 nM and 0.23 nM for
T3-1 and CHO#3 cells, respectively. Bmax values of 1.1 (
T3-1 cells) and 0.3 pmol/mg of protein (CHO#3 cells) reflected high levels of membrane
expression in both cell systems (Fig. 1).

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 1.
125I-Buserelin binding to
membranes of T3-1 and CHO#3 cells.
Binding of increasing concentrations of 125I-buserelin to
10 µg of T3-1 cell membrane proteins (A) and 40 µg
of CHO#3 cell membrane protein (B) per sample was monitored.
Incubations were carried out for 90 min at room temperature as
described under "Experimental Procedures." Nonspecific binding was
determined in the presence of excess unlabeled buserelin (1 µM). Scatchard analyses of single representative out of
three independent experiments performed in triplicate are shown.
|
|
Insensitivity of GnRH-mediated Signaling to Pertussis Toxin in
T3-1 and CHO#3 Cells--
It has been suggested that PTX-sensitive
G proteins contribute to GnRH-induced IP production in primary
pituitary cells as well as activation of ERK-mitogen-activated protein
kinases in
T3-1 cells (23-25). To address the issue of GnRH
receptor coupling to G proteins of the Gi/o family in
T3-1 and CHO#3 cells, agonist-stimulated IP accumulation was
determined with or without PTX pretreatment (Fig.
2). As illustrated in Fig. 2,
A and D,
T3-1 as well as CHO#3 cells
responded to GnRH challenge with a concentration-dependent increase in IP accumulation with EC50 values of 2.8 and 1.4 nM for
T3-1 and CHO#3 cells, respectively. PTX
pretreatment neither affected basal nor GnRH (1 µM)-stimulated IP production in
T3-1 (Fig.
2B) and CHO#3 (Fig. 2E) cells. To check whether
PTX was active in these experiments, IP accumulation due to activated endogenously expressed LPA receptors was measured as recently demonstrated for human fibroblasts (26). Fig. 2, C and
F, illustrates that LPA-induced IP production in
T3-1 as
well as in CHO#3 cells were completely blocked with PTX
pretreatment.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 2.
PTX-insensitive IP accumulation by the GnRH
receptor. T3-1 (A-C) and CHO#3 (D-F)
cells were seeded in 12-well plates and incubated in the presence of
PTX (0.1 µg/ml, three times at 12-h intervals prior to stimulation)
when indicated. IP accumulation was determined after 40 min of agonist
incubation. Determined EC50 values were 2.8 nM
for T3-1 cells (A) and 1.4 nM for CHO#3
cells (D). Data are means ± S.E. of three independent
experiments, each performed in triplicate.
|
|
In accord with our observations, PTX did also not affect GnRH-induced
calcium transients in the two cellular systems studied. When peak
intracellular Ca2+-concentrations in response to increasing
agonist concentrations were recorded in cells loaded with the
fluorescent Ca2+ indicator fura-2/AM, EC50
values of 1.2 and 0.1 nM were determined for
T3-1 (Fig.
3A) and CHO#3 cells (Fig.
3B), respectively. Compared with the half-maximal GnRH
concentrations needed for IP accumulation (see Fig. 2), the
concentration response curves depicted in Fig. 3 are left-shifted
toward lower agonist concentrations. No effect of PTX on the
agonist-induced calcium transients in either cell line was detected at
any hormone concentration tested (see Fig. 3). Viability of PTX was
confirmed using single cell fluorometrics as described previously (27);
LPA-induced Ca2+-ocillations in CHO#3 cells were completely
abolished after pretreatment with 100 ng/ml PTX (data not shown).

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 3.
PTX-insensitive Ca2+ mobilization
via the GnRH receptor. T3-1 (A) and CHO#3
(B) cells were detached and loaded with fura-2/AM in
incubation buffer (see under "Experimental Procedures").
Measurements were carried out with 1 × 106 cells/ml
in incubation buffer within seconds after the addition of agonist.
Fluorescence was monitored at 37 °C at various GnRH concentrations
for untreated ( ) or PTX-pretreated ( ) cells with an LS 50 B dual
wavelength fluorescence spectrophotometer (Perkin-Elmer).
|
|
To assess the participation of Gi/o proteins to
GnRH-induced ERK activation in aT3-1 cells, we performed ERK mobility
shift and in vitro kinase assays on whole cell lysates
obtained from for
T3-1 cells either stimulated with 1 µM GnRH, 100 ng/ml of the phorbol ester PMA or incubated
with 0.1% bovine serum albumin, serving as a control. GnRH-induced ERK
mobility shifts that mirror increased phosphorylation of ERKs were
observed for the 42-kDa isoform of ERK2 10 min after addition of GnRH
or PMA (Fig. 4). Pretreatment of cells
with 100 ng/ml PMA for 24 h to down regulate protein kinase C
isoforms completely suppressed ERK activation by GnRH or short-term PMA
challenge. On the contrary, preincubation of cells with PTX (100 ng/ml)
did not interfere with agonist-induced ERK activation (see Fig. 4).
Comparable results were obtained with the immune complex kinase assay
in which GnRH elicited a 2.7-fold ERK activation that was not inhibited
with PTX pretreatment but was blocked by the addition of the
GnRH-specific antagonist cetrorelix (10 µM). As a control
for PTX activity, ERK activation in response to 10 µM LPA
was blocked after pretreatment of
T3-1 cells with PTX (100 ng/ml).
Collectively, these data strongly argue against a participation of
Gi/o proteins in GnRH-evoked signaling pathways in
T3-1
and CHO#3 cells.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 4.
GnRH-mediated ERK2 activation in
T3-1 cells. A, cells were
incubated with (+) or without (-) 100 ng/ml PMA or 0.1 µg/ml PTX for 18 h. Confluent, serum-starved cells were then
challenged with 1% bovine serum albumin (control), 1 µM
GnRH, or 100 ng/ml PMA for 5 min. An ERK mobility shift assay (see
under "Experimental Procedures") was used to determine ERK
activation. Similar results were obtained in three independent
experiments. B, serum-starved cells in 100-mm dishes were
stimulated for 5 min with 200 nM GnRH or 10 µM LPA as indicated with (+) or without (-)
PTX pretreatment or in the presence of 10 µM cetrorelix
(antag.), which was added simultaneously with GnRH. ERK
activity was determined with an in vitro kinase assay using
myelin basic protein as a substrate (see under "Experimental
Procedures"). Data represent means ± S.E. of two independent
experiments, each performed in duplicate.
|
|
Inability of the GnRH Receptor to Couple to the Chimeric
Gsi5 Protein--
Several mutagenesis studies have shown
that the C terminus of the G protein
subunits plays a pivotal role
in defining the specificity of receptor/G protein interaction (28). In
particular, the C-terminal five amino acids are sufficient to switch
the receptor specificity of G
q/G
i2
chimeric proteins. Therefore, we took advantage of the chimeric G
protein
subunit Gsi5 characterized by the replacement
of the C-terminal five amino acids of Gs by the
corresponding amino acids of the Gi2, thus enabling a
Gi-activating receptor to stimulate adenylyl cyclase.
Transient expression in COS-7 cells of the human GnRH receptor in
conjunction with or without Gsi5 did not confer the ability
upon the agonist-bound receptor to initiate intracellular cAMP
production (Fig. 5). When expressed
alone, the activated m2 muscarinic receptor also failed to raise
intracellular cAMP levels, whereas carbachol stimulation of the m2
receptor coexpressed with Gsi5 led to clearly discernible cAMP accumulation (see Fig. 5). These data show that coexpression of
the Gsi5 chimera with Gi coupling receptors
results in cAMP production and further entertain the notion that the
human GnRH receptor is devoid of any Gi coupling
potential.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 5.
Coexpression of the GnRH receptor with the
chimeric G protein Gsi5. COS-7 cells were transfected
with cDNAs encoding the human GnRH receptor (GnRH-R, A)
or m2 muscarinic receptor (m2-R, B) in conjunction with or
without a chimeric G s protein (Gsi5) in
which the C-terminal five amino acids have been replaced by the
corresponding sequence of G i2. Following agonist
stimulation (A, 100 nM GnRH (filled
bars); B, 10 µM carbachol (filled
bars)) cAMP levels were determined as described (see under
"Experimental Procedures"). Data represent fold increases in
intracellular cAMP levels over controls (open bars, 350 ± 90 cpm/well) and are shown as means ± S.E. of two independent
experiments, each performed in triplicate.
|
|
Lack of GnRH-induced cAMP Production in
T3-1 and CHO#3
Cells--
Besides being able to couple to Gq/11 proteins,
the GnRH receptor has repeatedly been portrayed as a
Gs-activating receptor as well (29). Therefore, we tested
the ability of
T3-1 and CHO#3 cells to respond to GnRH stimulation
with increased cAMP accumulation (Fig.
6). Upon GnRH (1 µM)
challenge, the low intracellular cAMP levels remained indistinguishable
from baseline values, whereas CTX and forskolin induced profound cAMP
formation in
T3-1 (Fig. 6A) and CHO#3 (Fig.
6B) cells.

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 6.
cAMP formation in cells endogenously
expressing the mouse GnRH receptor ( T3-1)
(A) or stably transfected with the human GnRH receptor
cDNA (CHO#3) (B). Cells were either incubated
with 0.1% bovine serum albumin (basal) or with 1 µM
GnRH, 10 µg/ml CTX, or 20 µM forskolin for 1 h as
indicated. cAMP accumulation is expressed in cpm and represents
means ± S.E. of three independent experiments, each performed in
triplicate.
|
|
In an additional effort not to miss even small protracted rises in
intracellular cAMP levels evoked by GnRH stimulation, CHO#3 cells were
transiently transfected with a reporter plasmid (pADneo2-C6-BGL) containing the firefly luciferase gene under the transcriptional control of multiple cAMP response elements (13). CHO-V2-R cells permanently expressing the human V2 vasopressin receptor served as a
positive control. Both cell lines were transfected with equal amounts
of reporter plasmid, and luciferase activity in whole cell lysates was
determined after a 5-h incubation with saturating concentrations of
GnRH and AVP or after addition of forskolin (Fig.
7). In CHO#3 cells, neither GnRH nor AVP
challenge resulted in increased luciferase activity, whereas forskolin
was effective in inducing reporter gene expression (Fig.
7A). The V2 vasopressin receptor-expressing CHO cells
responded to AVP stimulation with a substantial enhancement of
luciferase activity comparable to the one observed after forskolin
addition (Fig. 7B).

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 7.
Agonist-induced cAMP-responsive
element-dependent luciferase expression in CHO#3
(A) and CHO-V2R (B) cells
permanently expressing the human GnRH and V2 vasopressin receptors,
respectively. Subsequent to transient transfection of the two
clonal CHO cell lines with the pADneo2-C6-BGL expression vector, cells
were stimulated for 5 h with 20 µM forskolin, 1 µM GnRH, or 100 nM AVP as indicated.
Following cell lysis, cAMP-dependent luciferase gene
expression was monitored in a luminometer as explained under
"Experimental Procedures."
|
|
GnRH-mediated cAMP Production in COS-7 Cells via
Ca2+/Calmodulin-sensitive Adenylyl Cyclase I--
In
contrast to various reports on Gs-dependent
cAMP formation initiated by the activated GnRH receptor (12, 30), we
were unable to detect GnRH-stimulated cAMP production in
T3-1 and CHO#3 cells. In an attempt to reconcile these discrepant results, we
embarked on the hypothesis that GnRH-dependent
Ca2+ transients may activate
Ca2+/calmodulin-sensitive adenylyl cyclase isoforms (31).
One candidate enzyme, AC-I, is highly expressed in the pituitary gland
(32). Thus, COS-7 cells were cotransfected with GnRH receptor and AC-I cDNAs, and cAMP accumulation subsequent to hormonal treatment was
measured (Fig. 8). The Gs
coupling luteinizing hormone receptor served as a positive control. In
AC-I-expressing COS-7 cells, GnRH treatment resulted in a substantial
cAMP accumulation that was suppressed by the presence of the potent
GnRH receptor antagonist [D-pGlu1,
D-Phe2,
D-Trp3,6]-LH-RH (see Fig. 8). Increased
baseline cAMP-levels in AC-I expressing cells were interpreted to
reflect the basal activity of the enzyme.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 8.
GnRH-dependent cAMP production
after coexpression of the human GnRH receptor and adenylyl cyclase
I. Cos-7 cells grown in six-well plates were transfected with 0.5 µg of GnRH receptor or luteinizing hormone receptor (LH-R)
cDNA. In addition, the transfection mixture contained 1.5 µg of
either AC-I cDNA or control plasmid DNA (vector). cAMP accumulation
was determined in the absence (-) or presence (+) of
various ligands: 1 µM GnRH, 1 µM
[D-pGlu1, D-Phe2,
D-Trp3,6]-LH-RH, a GnRH receptor antagonist
(antag.), and 1 µM human chorionic
gonadotropin (hCG).
|
|
Exclusive Coupling of the GnRH Receptor to G Proteins of the
Gq/11 Family in
T3-1 and CHO#3 Cells--
To study
GnRH receptor/G protein interaction under in situ
conditions, G proteins in membranes prepared from
T3-1 (Fig.
9A) and CHO#3 (Fig.
9B) cells were photolabeled with the nonhydrolyzable GTP
analog [
-32P]GTP azidoanilide in the absence or
presence of saturating GnRH concentrations. Stimulation with 1 µM GnRH led to an increased incorporation of
radioactivity into Gq/11 proteins (Fig. 9, A and
B), whereas the other PTX-insensitive G protein families, G12/13 and Gs, were not activated (see Fig. 9,
A and B). PTX-sensitive Gi and
Go proteins were also found not to productively interact with the agonist-bound GnRH receptor (see Fig. 9, A and
B). To show that the GnRH receptor effect on
Gq/11 proteins was specific in
T3-1 and CHO#3 cells, an
antagonist control experiment using 10 µM cetrorelix was
performed (see Fig. 9C). G protein expression in specific in
T3-1 and CHO#3 cells was confirmed by immunoblotting (see Fig.
9D).


View larger version (4744K):
[in this window]
[in a new window]
|
Fig. 9.
Activated G proteins in membrane preparations
from T3-1 (A and
C) and CHO#3 (B and
C) cells stimulated with 1 µM GnRH. Membranes (100 µg/tube
for T3-1 or 75 µg/tube for CHO#3 cells) were photolabeled with
[ -32P]GTP azidoanilide in the absence (-) or presence
(+) of GnRH and immunoprecipitated with the s,
q/11, 12, 13 or
q/11, i common (A and
B), and o common (A) antisera or
with q/11 antibodies alone (C) as described.
In C, the GnRH antagonist cetrorelix (10 µM)
was added together with GnRH (lanes 3 and 6) to
membranes from T3-1 (lanes 1-3) and CHO#3 (lanes
3-6). Precipitated proteins were resolved in SDS-polyacrylamide
gels and visualized by autoradiography. Molecular mass markers are
indicated. Similar results were obtained in four (A) or two
(B and C) independent experiments. D,
membrane proteins of T3-1 and CHO#3 cells (50 µg per lane) were
resolved on 10% SDS-polyacrylamide gels and subsequently blotted onto
nitrocellulose membrane. Membranes were cut into strips and incubated
with antisera against G subunits as indicated. Molecular mass
markers are shown on the right.
|
|
 |
DISCUSSION |
In the gonadotrope, GnRH elicits several distinct physiological
responses via activation of a single class of membrane receptors (2,
12). One possibility to explain the engagement of parallel signal
transduction pathways at the molecular level is the activation of
several G proteins by a single agonist-occupied receptor (33). Along
these lines, the proposal has recently been put forward that apart from
interacting with Gq/11 proteins (34), the GnRH receptor
would also activate Gi and Gs proteins (12).
Moreover, the propensity of the GnRH receptor to couple to multiple G
proteins was inferred not to be gonadotrope-specific but rather to
represent an inherent ability of the GnRH receptor itself (12). To test this frequently reiterated paradigm of the multiple G protein coupling
ability of the GnRH receptor (2, 12, 23, 35, 36), we set out to study
the G protein coupling profile of the murine GnRH receptor endogenously
expressed in
T3-1 cells as well as of the human receptor (22) in
CHO-K1 and COS-7 cells.
Functional studies on the GnRH receptor have been greatly facilitated
by the development of the
T3-1 cell line isolated from anterior
pituitary tumors of transgenic mice (37). Consistent with their
derivation from the gonadotrope lineage, glycoprotein hormone
-subunit is synthesized and secreted by these cells. In our studies,
the total number of specific binding sites for GnRH analogues amounted
to 1.1 pmol/mg of protein, slightly higher than those for normal mouse
(0.33 pmol/mg) and rat (0.31 pmol/mg) pituitary (38), whereas the
Bmax values for CHO#3 cell membranes (0.3 pmol/mg) heterologously expressing the the human GnRH receptor cDNA
were identical with those obtained for pituitary membranes. Kd values in the subnanomolar to low nanomolar range reflected high affinity binding of the GnRH superagonist
125I-buserelin to two cell models examined by us. Whereas
these data conform to those reported by McArdle et al. (39),
they contrast with a rather low binding affinity of
125I-buserelin (Kd = 41 nM)
to the recombinant rat GnRH receptor stably expressed in
GH3 somatotropes (30). Considering the similarity of
binding characteristics between our experimental systems and
gonadotropic cells, it is unlikely that receptor/G protein interaction
was substantially affected by receptor overexpression.
When GnRH-induced phospholipase C-
activation was studied in
T3-1 and CHO#3 cells, we were unable to detect any inhibitory effect of PTX pretreatment on IP formation and Ca2+
mobilization. However, in our hands, a similar regimen substantially reduced IP formation via Gi-coupled receptors (18).
Stimulation of phospholipase C activity by Gi coupling
receptors is thought to occur via G
subunits released from
activated Gi proteins (40). The observation that transient
expression of a C-terminal
-adrenergic receptor kinase (GRK2)
peptide (
ARK-ct) serving as a G
sequestrant suppresses
GnRH-dependent IP formation in GH3 cells stably
transfected with the rat GnRH receptor, appears to be compatible with
the latter notion (41). However, as other presumably
Gi-independent signaling pathways, e.g. cAMP
release, are similarly suppressed in the latter study (41), the
functional sequelae of
ARK-ct expression are not necessarily
indicative of GnRH-induced Gi activation. A general
impairment of G protein mediated signaling processes due to a
quantitative sequestration of G
subunits cannot be ruled out
under the above-mentioned experimental conditions.
GnRH-mediated ERK activation in
T3-1 cells allegedly depends on a
dual mechanism involving protein kinase C on the one hand and
PTX-sensitive G proteins on the other hand (25). These observations are
at odds with our results, which do not at all entertain the notion of
an involvement of Gi/o proteins in
GnRH-dependent ERK activity but corroborate the finding
that protein kinase C activity plays a pivotal role in this signaling
pathway (42, 43).
To further assess a potential Gi coupling ability of the
human GnRH receptor, coexression studies with the chimeric G protein Gsi5, in which the C-terminal five amino acids of
Gs were replaced by the corresponding amino acids of
Gi2, were performed in COS-7 cells. Several previous
studies have shown that the C-terminal five amino acids play a key role
in dictating the specificity of receptor/G protein coupling (28).
Whereas coexpression of Gsi5 with the m2 muscarinic
receptor resulted in carbachol-induced cAMP accumulation, no functional
interaction between the GnRH receptor and the chimeric G protein was
observed. The notion of GnRH receptor/Gi interaction has
largely been derived from circumstantial evidence, for instance
agonist-dependent palmitoylation of G protein
-subunits
(12). In dispersed pituitary cell cultures, however, a challenge with
phorbol myristic acid, a protein kinase C activator, was able to
partially mimic the GnRH effect (44), thus casting doubts on the
specificity of the experimental approach chosen. Moreover, when
down-regulation of activated G proteins was used as a read-out system,
stimulation of
T3-1 cells with a GnRH agonist resulted in enhanced
agonist-dependent proteolysis of Gq/11
proteins, whereas Gi2 remained unaffected (45). In keeping
with the latter findings, our data strongly suggest that human and
mouse GnRH receptors are unable to couple to Gi proteins.
Treatment of rat pituitary cell cultures with CTX increases luteinizing
hormone release in response to GnRH (46), and it was subsequently
inferred that the GnRH receptor might be positively linked to adenylyl
cyclase. Whereas in gonadotropes GnRH-stimulated cAMP formation has
never been detected (12, 47), somatotropic GH3 pituitary
cells stably transfected with the rat GnRH receptor cDNA respond to
prolonged incubation (>24 h) with GnRH agonists in the presence of a
phosphodiesterase inhibitor with a modest increase in cAMP secretion
into the culture medium (30). Moreover, in permeabilized gonadotropes,
cAMP synergizes with Ca2+ and phorbol esters in stimulation
of exocytotic gonadotropin release (48), suggesting that the adenylyl
cyclase/cAMP and phospholipase C/Ca2+/diacylglycerol
pathways may converge at a later stage of the GnRH signal transduction pathway.
Therefore, we set out to examine whether GnRH stimulation of
T3-1
and CHO#3 cells would lead to increased cAMP formation. Dual coupling
of a single receptor to Gs and Gq/11 proteins
has been demonstrated for several G protein-coupled receptors (33), for
instance the H2 histamine (49) and the cholecystokinin type A receptor (50). In the two cell lines tested, GnRH was ineffective in
raising intracellular cAMP levels, whereas the inhibition of the
intrinsic GTPase activity of G
s and the direct
activation of adenylyl cyclase by CTX and forskolin, respectively,
resulted in marked cAMP accumulation. To determine whether the
activated GnRH receptor could provoke a subtle and prolonged increase
in the basal rate of cAMP formation, CHO#3 cells were transfected with
a reporter plasmid containing the firefly luciferase under the
transcriptional control of several cAMP-responsive elements (13).
However, no significant cAMP responses to GnRH were detectable.
Although our findings are consistent with other studies on gonadotropes
(51, 52), they differ from results with the recombinant rat GnRH
receptor heterologously expressed in Sf9 insect cells (53) or in
COS-7 cells (54). It is noteworthy, however, that in transfected
somatotropic GH3 (12, 29) as well as in COS-7 cells (54)
GnRH-initiated cAMP formation increases over at least 4 orders of
magnitude, whereas in the latter cell model, agonist-induced IP
formation is accomplished within 2 log orders of GnRH concentrations. Thus, it is imaginable that in GH3 and in COS-7 cells
GnRH-dependent cAMP formation is caused by mechanisms other
than adenylyl cyclase activation through Gs proteins, for
instance mediated by elevated cytosolic Ca2+ concentrations
(31). Certain adenylyl cyclase isoforms (AC-I and AC-III) can be
activated independently from Gs by
Ca2+/calmodulin, and the AC-I isoform was found to be
expressed in the anterior piuitary gland (32). Along these lines,
GnRH-dependent cAMP formation could be reconstituted in
COS-7 cells by coexpression of the human GnRH receptor together with
AC-I, thus delineating an alternative signaling pathway that may help
to reconcile some of the conflicting results obtained when studying
GnRH-stimulated cAMP formation in different cell systems. In addition,
we cannot exclude the possibility that species differences between the
mouse and human receptors studied by us and the rat receptor (30, 54)
may contribute to the discrepant functional data. Mammalian GnRH
receptors lack intracellular C termini that have been implicated in
receptor expression and receptor/G protein interaction and desensitization phenomena (55, 56). Interestingly, the recently cloned
catfish GnRH receptor posesses a C-terminal tail, and
GnRH-dependent cAMP production in transfected 293T cells
was detected (56, 57). However, as yet, it is unclear whether this
property relates to the structural peculiarity of the receptor and
whether activation of Gs proteins underlies the latter
signaling pathway.
By definition, receptor-catalyzed GDP/GTP exchange is the sole direct
measure to monitor G protein activation, whereas other approaches, such
as the recording of changes in the palmitoylation pattern of G protein
subunits (29), yield only indirect results. Therefore, the
experimental approach that was chosen to monitor GnRH receptor/G
protein interaction consisted of a combination of
receptor-dependent photolabeling of G protein
subunits
with subsequent immunoprecipitation. Photolabeling experiments
employing the nonhydrolyzable GTP analog [
-32P]GTP
azidoanilide showed that in membranes of gonadotropic
T3-1 cells or
of CHO#3 cells the GnRH receptor couples neither to Gi nor
to Gs or G12/13 proteins but exclusively
activates Gq/11 proteins. The experimental approach has
previously been adopted for the signaling analysis of various G
protein-coupled receptors (18, 49). Thus, we show in the present study
that the GnRH receptor physiologically expressed in gonadotropic cells
elicits multiple cellular responses via selective coupling to
Gq/11 proteins.
The observation that many hormones and neurotransmitters evoke a
plethora of physiological responses led to the concept of G
protein-mediated signal transduction as a complex signaling network
with divergent and convergent pathways at each transduction level (33).
Thus, very rarely does signal transduction occur in a strictly linear
fashion, e.g. one receptor coupling to one G protein
subsequently activating one effector. In fact, most G protein-coupled
receptors have the propensity to interact with more than one G protein
family (58). In the present study, we provide evidence that the murine
GnRH receptor in gonadotropic cells and the human GnRH receptor
heterologously expressed in CHO-K1 and COS-7 cells exclusively couple
to G proteins of the Gq/11 family. In the case of the GnRH
receptor, signaling diversity occurs at a level downstream of the
receptor/G protein interface and does not reflect multiple coupling
potential of a single type of receptor. Therefore, the GnRH receptor
represents a valuable tool to study in depth the cellular events in
response to a single class of activated G proteins.
 |
ACKNOWLEDGEMENTS |
We are grateful to Rita Haubold for excellent
technical assistance with photolabeling experiments. We also thank
Thomas Hofmann for expert advice regarding single cell calcium monitoring.
 |
FOOTNOTES |
*
This work was supported by the Deutsche
Forschungsgemeinschaft and Fonds der Chemischen Industrie.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence should be addressed. Tel.: 49-30-8445-1818;
Fax: 49-30-162-8445-1818; E-mail: guderman@zedat.fu-berlin.de.
 |
ABBREVIATIONS |
The abbreviations used are:
GnRH, gonadotropin-releasing hormone;
AC-I, adenylyl cyclase type I;
AVP, arginine-vasopressin;
CTX, cholera toxin;
DMEM, Dulbecco's modified
Eagle's medium;
ERK, extracellular signal-regulated protein kinase;
fura-2/AM, fura-2/acetoxymethylester;
G protein, heterotrimeric guanine
nucleotide-binding protein;
IP, inositol phosphate;
LPA, lysophosphatidic acid;
PMA, phorbol myristate acetate;
PTX, pertussis
toxin.
 |
REFERENCES |
| 1.
|
Hotchkiss, J.,
and Knobil, E.
(1994)
Raven Press, New York
2,
711-750
|
| 2.
|
Kaiser, U. B.,
Conn, P. M.,
and Chin, W. W.
(1997)
Endocr. Rev.
18,
46-70[Abstract/Free Full Text]
|
| 3.
|
Childs, G. V.
(1995)
Vitam. Horm.
50,
215-286[Medline]
[Order article via Infotrieve]
|
| 4.
|
Flanagan, C. A.,
Millar, R. P.,
and Illing, N.
(1997)
Rev. Reprod.
2,
113-120[Abstract]
|
| 5.
|
Stojilkovic, S. S.,
Reinhart, J.,
and Catt, K. J.
(1994)
Endocr. Rev.
15,
462-499[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Emons, G.,
Muller, V.,
Ortmann, O.,
and Schulz, K. D.
(1998)
J. Steroid Biochem. Mol. Biol.
65,
199-206[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Pinski, J.,
Reile, H.,
Halmos, G.,
Groot, K.,
and Schally, A. V.
(1994)
Int. J. Cancer
59,
51-55[Medline]
[Order article via Infotrieve]
|
| 8.
|
Irmer, G.,
Bürger, C.,
Müller, R.,
Ortmann, O.,
Peter, U.,
Kakar, S. S.,
Neill, J. D.,
Schulz, K. D.,
and Emons, G.
(1995)
Cancer Res.
55,
817-822[Abstract/Free Full Text]
|
| 9.
|
Kakar, S. S.
(1998)
Cancer Res.
58,
4558-4560[Abstract/Free Full Text]
|
| 10.
|
Kakar, S. S.,
Grizzle, W. E.,
and Neill, J. D.
(1994)
Mol. Cell. Endocrinol.
106,
145-149[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Yano, T.,
Pinski, J.,
Halmos, G.,
Szepeshazi, K.,
Groot, K.,
and Schally, A.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
7090-7094[Abstract/Free Full Text]
|
| 12.
|
Stanislaus, D.,
Pinter, J. H.,
Janovick, J. A.,
and Conn, P. M.
(1998)
Mol. Cell. Endocrinol.
144,
1-10[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Himmler, A.,
Stratowa, C.,
and Czernilofsky, A. P.
(1993)
J. Recept. Res.
13,
79-94[Medline]
[Order article via Infotrieve]
|
| 14.
|
Schmid, A.,
Thierauch, K. H.,
Schleuning, W. D.,
and Dinter, H.
(1995)
Eur. J. Biochem.
228,
23-30[Medline]
[Order article via Infotrieve]
|
| 15.
|
Schöneberg, T.,
Sandig, V.,
Wess, J.,
Gudermann, T.,
and Schultz, G.
(1997)
J. Clin. Invest.
100,
1547-1556[Medline]
[Order article via Infotrieve]
|
| 16.
|
Bradford, M. M.
(1972)
Anal. Biochem.
72,
248-254[CrossRef]
|
| 17.
|
Munson, P. J.,
and Rodbard, D.
(1980)
Anal. Biochem.
107,
220-239[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Herrlich, A.,
Kühn, B.,
Grosse, R.,
Schmid, A.,
Schultz, G.,
and Gudermann, T.
(1996)
J. Biol. Chem.
271,
16764-16772[Abstract/Free Full Text]
|
| 19.
|
Grynkiewicz, G.,
Poenie, M.,
and Tsien, R. Y.
(1985)
J. Biol. Chem.
260,
3440-3450[Abstract/Free Full Text]
|
| 20.
|
Laugwitz, K.-L.,
Spicher, K.,
Schultz, G.,
and Offermans, S.
(1994)
Methods Enzymol.
237,
283-294[Medline]
[Order article via Infotrieve]
|
| 21.
|
Allgeier, A.,
Offermanns, S.,
Van Sande, J.,
Spicher, K.,
Schultz, G.,
and Dumont, J. E.
(1994)
J. Biol. Chem.
269,
13733-13735[Abstract/Free Full Text]
|
| 22.
|
Grosse, R.,
Schöneberg, T.,
Schultz, G.,
and Gudermann, T.
(1997)
Mol. Endocrinol.
11,
1305-1318[Abstract/Free Full Text]
|
| 23.
|
Hawes, B. E.,
Barnes, S. M.,
and Conn, P. M.
(1993)
Endocrinology
132,
2124-2130[Abstract]
|
| 24.
|
Barnes, S. J.,
and Conn, P. M.
(1993)
Endocrinology
133,
2756-2760[Abstract]
|
| 25.
|
Sim, P. J.,
Wolbers, W. B.,
and Mitchell, R.
(1995)
Mol. Cell. Endocrinol.
112,
257-263[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Pietruck, F.,
Busch, S.,
Virchow, S.,
Brockmeyer, N.,
and Siffert, W.
(1997)
Naunyn-Schmiedeberg's Arch. Pharmacol.
355,
1-7[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Hofmann, T.,
Obukhov, A. G.,
Schäfer, M.,
Harteneck, C.,
Gudermann, T.,
and Schultz, G.
(1999)
Nature
397,
259-263[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Liu, J.,
Conklin, B. R.,
Blin, N.,
Yun, J.,
and Wess, J.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
11642-11646[Abstract/Free Full Text]
|
| 29.
|
Stanislaus, D.,
Ponder, S.,
Ji, T. H.,
and Conn, P. M.
(1998)
Biol. Reprod.
59,
579-586[Abstract/Free Full Text]
|
| 30.
|
Kuphal, D.,
Janovick, J. A.,
Kaiser, U. B.,
Chin, W. W.,
and Conn, P. M.
(1994)
Endocrinology
135,
315-320[Abstract]
|
| 31.
|
Sunahara, R. K.,
Dessauer, C. W.,
and Gilman, A. G.
(1996)
Annu. Rev. Pharmacol. Toxicol.
36,
461-480[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Antoni, F. A.,
Barnard, R. J. O.,
Shipston, M. J.,
Smith, S. M.,
Simpson, J.,
and Paterson, J. M.
(1995)
J. Biol. Chem.
270,
28055-28061[Abstract/Free Full Text]
|
| 33.
|
Gudermann, T.,
Kalkbrenner, F.,
and Schultz, G.
(1996)
Annu. Rev. Pharmacol. Toxicol.
36,
429-459[Medline]
[Order article via Infotrieve]
|
| 34.
|
Hsieh, K.-P.,
and Martin, T. F. J.
(1992)
Mol. Endocrinol.
6,
1673-1681[Abstract]
|
| 35.
|
Hawes, B. E.,
Marzen, J. E.,
Waters, S. B.,
and Conn, P. M.
(1992)
Endocrinology
130,
2465-2475[Abstract]
|
| 36.
|
Ulloa-Aguirre, A.,
Stanislaus, D.,
Arora, V.,
Väänänen, J.,
Brothers, S.,
Jannovick, J. A.,
and Conn, P. M.
(1998)
Endocrinology
139,
2472-2478[Abstract/Free Full Text]
|
| 37.
|
Windle, J. J.,
Weiner, R. I.,
and Mellon, P. L.
(1990)
Mol. Endocrinol.
4,
597-603[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Horn, F.,
Bilezikjian, L. M.,
Perrin, M. H.,
Bosma, M. M.,
Windle, J. J.,
Huber, K. S.,
Bount, A. L.,
Hille, B.,
Vale, W.,
and Mellon, PL
(1991)
Mol. Endocrinol.
5,
347-355[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
McArdle, C. A.,
Schomerus, E.,
Groner, I.,
and Poch, A.
(1992)
Mol. Cell. Endocrinol.
87,
95-103[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Rhee, S. G.,
and Bae, Y. S.
(1997)
J. Biol. Chem.
272,
15045-15048[Free Full Text]
|
| 41.
|
Guo, C. H.,
Janovick, J. A.,
Kuphal, D.,
and Conn, P. M.
(1995)
Endocrinology
136,
3031-3036[Abstract]
|
| 42.
|
Sundaresan, S.,
Colin, I. M.,
Pestell, R. G.,
and Jameson, J. L.
(1996)
Endocrinology
137,
304-311[Abstract]
|
| 43.
|
Reiss, N.,
Llevi, L. N.,
Shacham, S.,
Harris, D.,
Seger, R.,
and Naor, Z.
(1997)
Endocrinology
138,
1673-1682[Abstract/Free Full Text]
|
| 44.
|
Stanislaus, D.,
Janovick, J. A.,
Brothers, S.,
and Conn, P. M.
(1997)
Mol. Endocrinol.
11,
738-746[Abstract/Free Full Text]
|
| 45.
|
Shah, B. H.,
MacEwan, D. J.,
and Milligan, G.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
1886-1890[Abstract/Free Full Text]
|
| 46.
|
Janovick, J. A.,
and Conn, P. M.
(1993)
Endocrinology
132,
2131-2135[Abstract]
|
| 47.
|
McArdle, C. A.,
and Counis, R.
(1996)
Endocrinol. Metab.
7,
168-175[CrossRef]
|
| 48.
|
Macrae, M. B.,
Davidson, J. S.,
Millar, R. P.,
and van der Merwe, P. A.
(1990)
Biochem. J.
271,
635-639[Medline]
[Order article via Infotrieve]
|
| 49.
|
Kühn, B.,
Schmid, A.,
Harteneck, C.,
Gudermann, T.,
and Schultz, G.
(1996)
Mol. Endocrinol.
10,
1697-1707[Abstract]
|
| 50.
|
Wu, V.,
Yang, M.,
McRoberts, J. A.,
Ren, J.,
Seensalu, R.,
Zeng, N.,
Dagrag, M.,
Birnbaumer, M.,
and Walsh, J. H.
(1997)
J. Biol. Chem.
272,
9037-9042[Abstract/Free Full Text]
|
| 51.
|
Shah, B. H.,
and Milligan, G.
(1994)
Mol. Pharmacol.
46,
1-7[Abstract]
|
| 52.
|
Schomerus, E.,
Poch, A.,
Bunting, R.,
Mason, W. T.,
and McArdle, C. A.
(1994)
Endocrinology
134,
315-323[Abstract]
|
| 53.
|
Delahaye, R.,
Manna, P. R.,
Berault, A.,
Berreur-Bonnenfant, J.,
Berreur, P.,
and Counis, R.
(1997)
Mol. Cell. Endocrinol.
135,
119-127[CrossRef][Medline]
[Order article via Infotrieve]
|
| 54.
|
Arora, K. K.,
Krsmanovic, L. Z.,
Mores, N.,
O'Farrell, H.,
and Catt, K. J.
(1998)
J. Biol. Chem.
273,
25581-25586[Abstract/Free Full Text]
|
| 55.
|
Heding, A.,
Vrecl, M.,
Bogerd, J.,
McGregor, A.,
Sellar, R.,
Taylor, P. L.,
and Eidne, K. A.
(1998)
J. Biol. Chem.
273,
11472-11477[Abstract/Free Full Text]
|
| 56.
|
Lin, X.,
Janovick, J. A.,
Brothers, S.,
Blömenrohr, M.,
Bogerd, J.,
and Conn, P. M.
(1998)
Mol. Endocrinol.
12,
161-171[Abstract/Free Full Text]
|
| 57.
|
Blomenröhr, M.,
Bogerd, J.,
Leu |